A leader in neuro-scientific human gene therapy.

‘Specifically, our positive results in the heart and respiratory muscles bring hope that we might be able to prevent the fatal outcome of the disease later on, through a long-term remedy with an individual treatment potentially.’.. AMT’s gene therapy successful in treating Duchenne muscular dystrophy Amsterdam Molecular Therapeutics , a leader in neuro-scientific human gene therapy, announced today that it has successfully treated Duchenne muscular dystrophy within an animal model using its proprietary gene therapy. The proof concept studies were performed in collaboration with the group of Professor Irene Bozzoni and demonstrated efficiency in the heart and also in skeletal muscle tissues.You might be surprised at what you decide to eat regularly.. 3D structure of PI3Kdelta: A significant drug target for a wide range of diseases Intellikine announced today the publication of articles entitled, ‘The p110delta framework: mechanisms for selectivity and potency of brand-new PIK inhibitors,’ available as a sophisticated online publication at Character Chemical Biology now. The paper provides the initial glimpse at the three-dimensional framework of PI3Kdelta , an important drug target implicated in a wide range of diseases, including cancers, rheumatoid and asthma arthritis. The pioneering function was the total result of a collaboration led by Roger Williams, Ph.D., Professor in the Laboratory of Molecular Biology at the Medical Study Council in Cambridge, U.K., and it included researchers from the University of California, San Francisco, Intellikine in La Jolla, California, and Merck-Serono Study Center in Geneva, Switzerland.